gallstone disease
Conditions
Interventions
Experimental group:TUDCA at a dose of 250mg, 3 times daily for 48 weeks
Control:No Intervention
Sponsors
Wuhan Union Hospital Affiliated with Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) aged 18 to 70 years, male and female; 2) the diagnosis of B ultrasound was confirmed, the CT value was less than 150 HU, and there was no calcification in the core or periphery of the stone; 3) the maximum diameter of stone <10 mm, be relaxed properly for those who insisted on attending the clinical trial; 4) the patient was examined for stones, asymptomatic or only mild upper abdominal fullness after meals, hiccup; 5) informed consent was signed.
Exclusion criteria
Exclusion criteria: 1) Ultrasound B showed intrahepatic and extrahepatic bile duct dilatation; 2) Ultrasound B showed cholecystolithiasis combine with intrahepatic and extrahepatic bile duct calculus; 3) CT > 150 HU, core or peripheral calcification; 4) Severe heart, brain, lung, liver, kidney disease, and severe hypertension; 5) Severe endocrine, blood and neuropsychiatric disorders; 6) Pregnant or lactating women with recent fertility plans; 7) Allergic to study drugs and Persons with hypersensitivity; 8) Other circumstances that the researchers consider unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prominent rate and effective rate after 24 weeks treatment for gallstone disolution; | — |
Secondary
| Measure | Time frame |
|---|---|
| Prominent rate and effective rate after 48 weeks treatment for gallstone disolution, and Serum biochemical parameters change; | — |
Countries
China
Contacts
Public ContactXiao-Hua Hou
Digestive Medicine Department, Wuhan Union Hospital Affiliated with Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed